{"schema_version":"secwatch.filing_event.v1","accession":"0000320017-25-000059","form_type":"8-K","ticker":"LSTA","cik":"0000320017","company_name":"LISATA THERAPEUTICS, INC.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.046780+00:00","generated_at":"2026-05-17T18:33:47.851227+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lisata Q2 net loss $4.7M, cash $22M; certepetide trials advancing with multiple data milestones ahead","bullets":["Net loss of $4.7M vs $5.0M in Q2 2024; revenue of $70K from Catalent license fee.","Cash, equivalents and securities total $22.0M; runway into Q4 2026 funds all active trials to next data milestone.","ASCEND Phase 2b Cohort B showed positive PFS and ORR signal; final data expected late 2025.","BOLSTER Phase 2a first-line CCA enrollment complete; topline data due Q4 2025.","USPTO issued new composition-of-matter patent for certepetide (U.S. 12,351,653) extending protection to March 2040."],"urls":{"canonical":"https://secwatch.observer/filing/0000320017-25-000059","json":"https://secwatch.observer/filing/0000320017-25-000059.json","markdown":"https://secwatch.observer/filing/0000320017-25-000059.md","text":"https://secwatch.observer/filing/0000320017-25-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/320017/000032001725000059/0000320017-25-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/320017/000032001725000059/clbs-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:33:47.851227+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}